Lv4
460 积分 2024-08-28 加入
Chemoimmunotherapy synergism: mechanisms and clinical applications
1小时前
待确认
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS
2个月前
已完结
MET Enhances Amivantamab Binding to EGFR and Antibody‐Dependent Cellular Toxicity
2个月前
已完结
6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
2个月前
已完结
Landmark PALOMA and MARIPOSA Studies Reveal the Impact of Amivantamab Alone and Combined with Lazertinib in Advanced NSCLC
2个月前
已关闭
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)
2个月前
已关闭
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
2个月前
已完结
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
2个月前
已完结
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management
3个月前
已完结
皖公网安备34019202002308
